S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The 3-Stock Retirement Blueprint (Ad)
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
Denmark says Nord Stream 1 pipelines stop leaking
The 3-Stock Retirement Blueprint (Ad)
Ruptured oil pipeline off California approved for repairs
US shift away from coal hits tribal community in New Mexico
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The 3-Stock Retirement Blueprint (Ad)
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
Denmark says Nord Stream 1 pipelines stop leaking
The 3-Stock Retirement Blueprint (Ad)
Ruptured oil pipeline off California approved for repairs
US shift away from coal hits tribal community in New Mexico
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The 3-Stock Retirement Blueprint (Ad)
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
Denmark says Nord Stream 1 pipelines stop leaking
The 3-Stock Retirement Blueprint (Ad)
Ruptured oil pipeline off California approved for repairs
US shift away from coal hits tribal community in New Mexico
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The 3-Stock Retirement Blueprint (Ad)
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
Denmark says Nord Stream 1 pipelines stop leaking
The 3-Stock Retirement Blueprint (Ad)
Ruptured oil pipeline off California approved for repairs
US shift away from coal hits tribal community in New Mexico

Trevi Therapeutics - TRVI Stock Forecast, Price & News

$1.54
0.00 (0.00%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.43
$1.79
50-Day Range
$1.54
$4.28
52-Week Range
$0.46
$4.68
Volume
840,684 shs
Average Volume
327,148 shs
Market Capitalization
$67.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Trevi Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
592.6% Upside
$10.67 Price Target
Short Interest
Healthy
0.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$197,700 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.62) to ($0.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

387th out of 1,095 stocks

Pharmaceutical Preparations Industry

172nd out of 547 stocks

TRVI stock logo

About Trevi Therapeutics (NASDAQ:TRVI) Stock

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRVI Stock News Headlines

/C O R R E C T I O N -- Trevi Therapeutics, Inc./
Trevi Therapeutics Announces Proposed Public Offering
Trevi Therapeutics: Moving Forward
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Update
Why Did Needham Lift Price Target For Trevi?
Why Trevi Therapeutics Shares Trading Higher Today?
See More Headlines
Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRVI Company Calendar

Last Earnings
8/11/2022
Today
10/02/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRVI
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.67
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+592.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-33,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.66 per share

Miscellaneous

Free Float
26,654,000
Market Cap
$67.87 million
Optionable
Not Optionable
Beta
0.20

Key Executives

  • Ms. Jennifer L. Good (Age 57)
    Co-Founder, CEO, Pres & Director
    Comp: $731.41k
  • Dr. Thomas R. Sciascia (Age 69)
    Co-Founder & Chief Medical Officer
    Comp: $499.65k
  • Dr. William P. Forbes Pharm. D. (Age 60)
    Pharm.D., Chief Devel. Officer
    Comp: $596.74k
  • Ms. Lisa Delfini (Age 52)
    Chief Financial Officer
  • Mr. Christopher Galletta (Age 44)
    Controller & Chief Accounting Officer
  • Mr. Frank P. Muscolo (Age 65)
    Exec. Officer
  • Ms. Danine Summers (Age 64)
    VP of Medical Affairs













TRVI Stock - Frequently Asked Questions

Should I buy or sell Trevi Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TRVI shares.
View TRVI analyst ratings
or view top-rated stocks.

What is Trevi Therapeutics' stock price forecast for 2022?

3 Wall Street research analysts have issued 12-month price targets for Trevi Therapeutics' shares. Their TRVI share price forecasts range from $10.00 to $12.00. On average, they predict the company's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 592.6% from the stock's current price.
View analysts price targets for TRVI
or view top-rated stocks among Wall Street analysts.

How have TRVI shares performed in 2022?

Trevi Therapeutics' stock was trading at $0.7822 at the beginning of the year. Since then, TRVI shares have increased by 96.9% and is now trading at $1.54.
View the best growth stocks for 2022 here
.

When is Trevi Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our TRVI earnings forecast
.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced its quarterly earnings data on Thursday, August, 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07.

What other stocks do shareholders of Trevi Therapeutics own?
When did Trevi Therapeutics IPO?

(TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Trevi Therapeutics' stock symbol?

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

How do I buy shares of Trevi Therapeutics?

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevi Therapeutics' stock price today?

One share of TRVI stock can currently be purchased for approximately $1.54.

How much money does Trevi Therapeutics make?

Trevi Therapeutics (NASDAQ:TRVI) has a market capitalization of $67.87 million. The company earns $-33,940,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

How can I contact Trevi Therapeutics?

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The official website for the company is www.trevitherapeutics.com. The company can be reached via phone at (203) 304-2499 or via email at peter.vozzo@westwicke.com.

This page (NASDAQ:TRVI) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.